Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes
Status:
Completed
Trial end date:
2008-11-15
Target enrollment:
Participant gender:
Summary
This study is conducted in Asia, Europe, Japan and North America. The aim of this
observational study is to evaluate the safety and effectiveness while using NovoMix® 30
during 26 weeks under normal clinical practice, in the countries participating in the study.
The primary outcome is the incidence of major hypoglycaemic events reported as serious
adverse drugs reaction conditions on hypoglycaemic events.